Skip to main
TNYA
TNYA logo

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc. has demonstrated promising advancements in its gene therapy programs, particularly with consistent improvements in left ventricular posterior wall thickness (LVPWT) and left ventricular mass index (LVMI) among patients, which could facilitate accelerated approval pathways. The positive safety reviews from independent Data Safety and Monitoring Boards for ongoing trials of TN-201 and TN-401 further bolster investor confidence, indicating a secure progression through clinical phases. Additionally, the trends observed in key cardiac biomarker data, along with improvements in patients' NYHA classifications, suggest a solid potential for effective therapy in treating underlying drivers of heart disease.

Bears say

Tenaya Therapeutics Inc faces significant risks that may adversely affect its stock outlook, primarily due to potential delays in transitioning its preclinical assets to clinical trials and the emergence of critical safety signals related to immune reactions. Additionally, the company’s gene therapy products present complexities in manufacturing which could lead to further delays in development and commercialization, directly impacting financial forecasts. Lastly, variable patient outcomes demonstrated in preliminary data, along with uncertainty surrounding immune response management, pose additional challenges that may constrain the company's growth potential.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.